This trial is testing a combination of two different types of drugs to treat people with primary central nervous system lymphoma, a cancer of the lymph nodes in the brain and spinal cord. The study has enrolled three patients so far, but all three had a different type of CNS lymphoma (secondary, not primary) and they all progressed quickly despite treatment. So the study is being amended to only include patients with primary CNS lymphoma.
1 Primary · 5 Secondary · Reporting Duration: Completion of first 12 weeks of treatment within phase I portion of study (estimated to be 14 months)
Experimental Treatment
21 Total Participants · 3 Treatment Groups
Primary Treatment: Acalabrutinib · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: